Modality
Small Molecule
MOA
JAK1i
Target
PI3Kα
Pathway
Fibrosis
HNSCCHCCCF
Development Pipeline
Preclinical
~Mar 2022
→ ~Jun 2023
Phase 1
Sep 2023
Phase 1Current
NCT05934025
737 pts·CF
2023-09→TBD·Not yet recruiting
737 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05934025 | Phase 1/2 | CF | Not yet recr... | 737 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα |